Health Trials

KRAS G12C Lung Cancer

3

Review clinical trials related to KRAS G12C Lung Cancer. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

The purpose of this study is to evaluate the efficacy and safety of divarasib and pembrolizumab compared with pembrolizumab and pemetrexed and carboplatin or cisplatin, for the first-line treatment of adult participants with KRAS G12C-mutated, advanced or metastatic non squamous non-small cell lung cancer (NSCLC).

Participants needed: 600
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Hoffmann-La RocheUpdated: Jun 9, 2026Locations: 251
Eligibility criteria

Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 [+8]

Known concomitant second oncogenic driver with available targeted treatment [+16]

Read more
Status: Not yet recruiting

Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study)

This study is a multicenter, prospective, open-label clinical trial. It enrolls previously untreated patients with resectable stage IB-IIIB KRAS G12C mutation-positive NSCLC to evaluate the efficacy and safety of glesorasib sequentially combined with ivonescimab and chemotherapy as perioperative treatment for this patient population.

Participants needed: 32
Trial details
Phase: Phase 2Age: 18-80Biological sex: AllType: InterventionalSponsor: Guangdong Provincial People's HospitalUpdated: Mar 16, 2026
Eligibility criteria

Age Range: Males or females aged 18 years or older. [+16]

Previous receipt of any anti-tumor therapy for lung cancer (including adjuvant c... [+52]

Read more
Status: Not yet recruiting

A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patients With KRAS G12C Mutation

A multicenter, single-arm Phase II study to evaluate the efficacy and safety of fulzerasib (IBI351) in combination with ivonescimab (AK-112) in first-line treatment of advanced or metastatic non-small cell lung cancer patients with KRAS G12C mutation

Participants needed: 39
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Shanghai Chest HospitalUpdated: Apr 20, 2025
Eligibility criteria

Sign the Informed Consent Form (ICF) and be able to comply with the visit and re... [+7]

Experienced definite cardiovascular abnormal events within 6 months, such as myo... [+5]

Read more